China TCM is a traditional Chinese medicine company producing herbs, decoction pieces, concentrated granules, finished drugs, and great health products.
China Traditional Chinese Medicine Holdings Co. Limited (SEHK:570) has been excluded from the FTSE All-World Index. The move follows FTSE Russell’s periodic reviews of constituent companies in global equity benchmarks. The company specializes in traditional Chinese medicine products and healthcare services.
China Traditional Chinese Medicine Holdings’ two subsidiaries signed **21.9 million yuan** in contracts with **Pharmengin** to upgrade renovation and production facilities. The agreements aim to boost manufacturing capacity for traditional Chinese medicine products. The company’s subsidiaries will execute the projects under the partnership.
China Traditional Chinese Medicine Holdings secures NMPA approval for a new depression treatment. The company develops traditional Chinese medicine-based therapies for mental health conditions. This marks a regulatory milestone for its innovative approach in psychiatric care.
China Traditional Chinese Medicine (CTCM) reports a **27.1% year-over-year revenue drop to RMB5.44 billion**, alongside a **net loss of RMB834.7 million**. The decline stems from policy-driven reductions in sales of concentrated TCM granules and a **goodwill impairment**. Gross margins shrink to **47.5%**, and the company declares **no interim dividend** for shareholders.